Why tocilizumab could be an effective treatment for severe COVID-19?

A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Binqing, Xu, Xiaoling, Wei, Haiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154566/
https://www.ncbi.nlm.nih.gov/pubmed/32290839
http://dx.doi.org/10.1186/s12967-020-02339-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154566/
https://www.ncbi.nlm.nih.gov/pubmed/32290839
http://dx.doi.org/10.1186/s12967-020-02339-3

Ejemplares similares